Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 plus nivolumab in relapsed or refractory gastric, gastro-esophageal junction, or esophageal adenocarcinoma
2020-004175-41Phase 2Completed
- Sponsor
- NeoImmuneTech
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alfa and nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by NeoImmuneTech. Primary endpoint: Objective response rate. Started Apr 2021; status: completed.
02
Drugs
efineptakin alfanivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2020-004175-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004175-41.